← All trials
NCT04939779
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 14, 2021
- Primary completion
- Jan 24, 2021
- Completion date
- Feb 1, 2021
- First posted
- Jun 25, 2021
- Last posted
- Jun 25, 2021
- Enrollment
- 25
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- LegoChem Biosciences, IncLead sponsor
- Seoul National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.